Compugen Ltd. (TLV:CGEN)
Israel
· Delayed Price · Currency is ILS · Price in ILA | Market Cap | 822.55M |
| Revenue (ttm) | 231.97M |
| Net Income (ttm) | 112.67M |
| Shares Out | n/a |
| EPS (ttm) | 1.21 |
| PE Ratio | 7.30 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,215 |
| Average Volume | 60,112 |
| Open | 900.00 |
| Previous Close | 904.00 |
| Day's Range | 839.10 - 900.00 |
| 52-Week Range | 435.00 - 924.00 |
| Beta | 2.77 |
| RSI | 62.35 |
| Earnings Date | May 18, 2026 |
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/T... [Read more]
Financial Performance
Financial numbers in USDNews
Compugen Transcript: 25th Annual Needham Virtual Healthcare Conference
The company showcased its AI-driven immune-oncology pipeline, highlighting COM701 and rilvegostomig, with major partnerships and robust financials. Key trials target platinum-sensitive ovarian cancer and innovative bispecific antibody strategies, with pivotal data expected from 2027 onward.
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...
Compugen Transcript: Leerink Global Healthcare Conference 2026
AstraZeneca's rilvegostomig is being tested in 11 phase III trials, leveraging a bispecific, Fc-reduced format and novel biomarker-driven combinations, with key readouts expected after 2027. COM701 is being evaluated in platinum-sensitive ovarian cancer, and an IL-18BP program with Gilead is advancing in phase I.
Compugen Earnings Call Transcript: Q4 2025
Cash runway extended into 2029 after a $65M AstraZeneca deal, with strong revenue growth and a shift to profitability in 2025. Key clinical programs advanced globally, with major milestones expected in 2026–2027.
Compugen Reports Fourth Quarter and Full Year 2025 Results
Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029 Enhanced leaders...
Compugen Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
COM701 is advancing in a randomized trial for platinum-sensitive ovarian cancer, aiming to extend progression-free survival, with interim data expected in Q1 2027. Partnerships with AstraZeneca and Gilead provide financial stability and support a robust early pipeline focused on novel immuno-oncology targets.
Compugen to Participate in Upcoming Investor Conferences
HOLON, Israel, Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/...
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
HOLON, Israel, Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI...
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
HOLON, Israel, Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI...
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential key catalysts from internal and partnered ...
Compugen Transcript: Stifel 2025 Healthcare Conference
The company highlighted its AI-driven immuno-oncology pipeline, including COM701 for ovarian cancer and GS-0321 for cytokine modulation, both advancing in clinical trials. Strategic partnerships with AstraZeneca and Gilead provide significant milestone and royalty opportunities, with a cash runway into Q3 2027.
Compugen Earnings Call Transcript: Q3 2025
Solid cash position supports operations into Q3 2027, with key clinical programs advancing and major catalysts expected in 2026. Revenue declined year-over-year due to milestone timing, while R&D and G&A expenses decreased. Clinical data and partnerships with AstraZeneca and Gilead drive future value.
Compugen Reports Third Quarter 2025 Results
COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian platform trial Enrolling patients in the U.S., Israel...
Compugen to Participate in Stifel 2025 Healthcare Conference
HOLON, Israel , Nov. 4, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery po...
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
HOLON, Israel , Oct. 27, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery p...
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Pooled analysis supports the rationale for the ongoing MAIA-ovarian trial evaluating COM701 as maintenance therapy in the earlier setting of platinum sensitive ovarian cancer HOLON, Israel , Oct. 13, ...
Compugen to Present at SITC 2025
HOLON, Israel , Oct. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered...
Compugen Transcript: Q3 Investor Summit Group Virtual Conference 2025
Leadership transition and a focus on AI-driven immuno-oncology mark a new phase, with a robust pipeline, major pharma partnerships, and strong financials supporting growth. Key clinical readouts and milestone opportunities are expected in the next few years.
Compugen to Present Research at the Single Cell Genomics 2025 Conference
HOLON, ISRAEL , Sept. 8, 2025 /PRNewswire/ -- Compugen Ltd.
Compugen Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The company leverages its Unigen™ AI platform to discover novel immuno-oncology targets, advancing assets like COM701 and COM902 through strategic partnerships with AstraZeneca and Gilead. The MAIA ovarian cancer study is a key focus, with interim results expected in 2026. Financially, a $94M cash position supports operations into 2027.
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
HOLON, Israel , Aug. 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powere...
Compugen Earnings Call Transcript: Q2 2025
Leadership transition and strong cash position support ongoing clinical progress in immuno-oncology, with key trials advancing and major partnerships offering significant milestone potential. Revenue declined year-over-year due to milestone timing, but cash runway extends into 2027.
Compugen Reports Second Quarter 2025 Results
First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025 Pooled analysis from three previously reported Phase 1 ...
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
HOLON, Israel , July 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery po...
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
HOLON, Israel , July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery p...